ROIV — Roivant Sciences Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1635088 ·
United Kingdom
Last close
$33.91
Market Cap
$24.50B
52W High
$37.00
52W Low
$27.52
ADV30
5,668,243
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,520,000 | 2,200,000 | -354,995,000 | 302,994,000 | 5,708,687,000 | 1,419,232,000 | 416,275,000 |
| Dec 2025 | 1,999,000 | 1,299,000 | -339,153,000 | -265,891,000 | 5,225,368,000 | 1,478,270,000 | 251,144,000 |
| Sep 2025 | 1,571,000 | 1,460,000 | -306,233,000 | -113,519,000 | 5,062,598,000 | 1,237,010,000 | 257,140,000 |
| Jun 2025 | 2,170,000 | 2,016,000 | -284,922,000 | -223,355,000 | 5,032,602,000 | 1,238,459,000 | 216,696,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-750,349,000
Investing CF
$-682,333,000
Financing CF
$134,236,000
CapEx
$-13,955,000
Dividends Paid
—
Buybacks
$-319,503,000
EPS Diluted TTM
$-0.60
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-501,814,000
Inventory
—
Receivables
$770,235,000
ST Investments
$2,872,601,000
EBIT TTM
$-1,285,303,000
Pretax Income TTM
$-264,578,000
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,260,000
EBITDA
$-1,276,555,008
Free Cash Flow
$-1,090,485,376
Enterprise Value
$20,971,106,304
Total Cash
$4,291,833,088
Total Debt
$107,438,000
Shares Out
722,406,273
Trailing EPS
$-0.54
Book Value
$6.29
ROE
-7.6%
ROA
-14.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,260,000 | -1,285,303,000 | -299,771,000 | 5,708,687,000 | 416,275,000 | — | -750,349,000 |
| Mar 2025 | 29,053,000 | -1,113,681,000 | -171,981,000 | 5,436,940,000 | 249,742,000 | — | -839,451,000 |
| Mar 2024 | 32,713,000 | -824,928,000 | 4,348,926,000 | 7,222,482,000 | 773,953,000 | — | -765,268,000 |
| Mar 2023 | 31,530,000 | -809,014,000 | -1,009,030,000 | 2,389,604,000 | 782,017,000 | — | -843,393,000 |
TTM Snapshot
Revenues TTM
$9,018,000
NetIncome TTM
$169,381,000
OpCashFlow TTM
$0
Assets (Latest)
$5,436,940,000
Forward EPS
$-1.56
Max Pain — expiry 2026-08-21
max pain strike: $28.00 · spot: $33.91 · call oi: 6,563 · put oi: 1,711
Expected Move to 2026-08-21:
±$4.05
(11.94%) —
implied range
$29.86 –
$37.96
· ATM straddle on $34.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS Corp | $25.78B | $517.71 | — |
| RPRX | Royalty Pharma plc | $25.90B | $58.43 | — |
| BEIGF | BeOne Medicines Ltd. | $27.08B | $21.95 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $27.50B | $205.52 | — |
| INSM | INSMED Inc | $21.37B | $98.60 | — |
News headlines (Yahoo Finance, 1h cache)
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
2026-07-29 12:25 · Yahoo
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
2026-07-23 20:05 · Yahoo
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
2026-07-23 20:05 · Yahoo
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to
2026-07-16 11:30 · Yahoo
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
2026-07-07 18:28 · Yahoo
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
2026-07-07 10:35 · Yahoo
Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory
2026-06-17 13:46 · Yahoo
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
2026-06-11 01:00 · Yahoo
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)
2026-06-09 17:41 · Yahoo
Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum
2026-05-26 06:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.